Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

@article{Krop2015FeasibilityAC,
  title={Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.},
  author={Ian Krop and Thomas M. Suter and Chau T. Dang and Luc Y Dirix and Gilles Romieu and Claudio Zamagni and Marc L. Citron and Mario Campone and Na Xu and Melanie C. Smitt and Luca Gianni},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 10},
  pages={
          1136-42
        }
}
PURPOSE Trastuzumab emtansine (T-DM1), an antibody-drug conjugate comprising the cytotoxic agent DM1, a stable linker, and trastuzumab, has demonstrated substantial activity in human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer, raising interest in evaluating the feasibility and cardiac safety of T-DM1 in early-stage breast cancer (EBC). PATIENTS AND METHODS Patients (N = 153) with HER2-positive EBC and prechemotherapy left ventricular ejection fraction (LVEF… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Trastuzumab emtansine for HER2-positive advanced breast cancer.

  • The New England journal of medicine
  • 2012
VIEW 6 EXCERPTS

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 1 EXCERPT